期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.689132
关键词
NSCLC; immunotherapy; immune checkpoint blockade; angiogenesis inhibitors; combination therapy; tumor microenvironment
类别
资金
- National Key Research and Development Program of China [2016YFA 0500304]
- National Nature Science Foundation in China (NSFC) [81802853, 81773052, 81572806, 82002400]
- Natural Science Foundation of Zhejiang Provincial [Y19H160116, Q18H160119]
- Postdoctoral Science Foundation in China [2018M633237]
- Guangzhou Science Technology and Innovation Commission [201607020038]
- Science and technology projects of Guangdong Province [2016A0 20215086]
- Guangdong Innovative and Entrepreneurial Research Team Program [2016ZT06S638]
- leading talents of Guangdong province program
Combining immunotherapy with anti-angiogenesis can transform the tumor microenvironment from immunosuppressive to immune-supportive, increasing the infiltration and activation of immune cells. Therefore, this combination is a promising strategy for cancer treatment.
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from the increase in the expression of pro-angiogenic factors, which is involved in the regulation of the function and migration of immune cells. Anti-angiogenic agents can normalize blood vessels, and thus transforming the tumor microenvironment from immunosuppressive to immune-supportive by increasing the infiltration and activation of immune cells. Therefore, the combination of immunotherapy with anti-angiogenesis is a promising strategy for cancer treatment. Here, we outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of ICB and anti-angiogenic drugs in the treatment of advanced NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据